Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N4T8
UPID:
CBR4_HUMAN
Alternative names:
3-ketoacyl-[acyl-carrier-protein] reductase beta subunit; Carbonyl reductase family member 4; Quinone reductase CBR4; Short chain dehydrogenase/reductase family 45C member 1
Alternative UPACC:
Q8N4T8; Q8WTW8; Q96K93
Background:
The 3-oxoacyl-[acyl-carrier-protein] reductase, a beta subunit of the KAR heterotetramer complex, plays a pivotal role in mitochondrial fatty acid biosynthesis. It reduces 3-oxoacyl-[ACP] to (3R)-hydroxyacyl-[ACP] in a NADPH-dependent manner, showcasing no preference for chain length. This enzyme, also known as Quinone reductase CBR4, exhibits versatility by reducing various quinones, contributing to cellular protection against cytotoxicity.
Therapeutic significance:
Understanding the role of 3-oxoacyl-[acyl-carrier-protein] reductase could open doors to potential therapeutic strategies.